Achieve Life Sciences, Inc. has released its financial results for the third quarter of 2026, emphasizing its ongoing advancements in the diagnostic sector. This update is crucial as it reflects the company's performance and strategic direction amidst a competitive landscape.
Background
Achieve Life Sciences, Inc. operates in the In Vitro & In Vivo Diagnostic Substances sector, with its stock traded on the Nasdaq under the ticker symbol ACHV. The company, incorporated in Delaware, focuses on developing innovative diagnostic solutions to improve patient outcomes. Recent filings include a 10-Q and an 8-K, both submitted on November 10, 2026, highlighting the company's financial status and operational updates.
What the Filing Says
The filing dated November 10, 2026, includes key insights into the company's financial condition and operational results. Specific details on revenue, expenses, and other financial metrics were not disclosed in the filing.
Impact
This financial update may significantly impact stakeholders, including investors, employees, and partners, as it outlines Achieve's performance in a competitive market. The advancements reported may also influence the strategies of other companies in the In Vitro & In Vivo Diagnostic Substances industry.
What's Next
The filing does not say what happens next.
Company Information
Achieve Life Sciences, Inc. is incorporated in Delaware and operates under the standard industrial classification of In Vitro & In Vivo Diagnostic Substances, specifically coded as 2835. The company maintains its headquarters at 22722 29th Drive SE, Suite 100, Seattle, WA 98021, and has a business phone number of 425-686-1500.
Former Names
Previously, Achieve Life Sciences was known as OncoGenex Pharmaceuticals, Inc., a name it adopted on August 21, 2008. Before that, it was called Sonus Pharmaceuticals Inc, changing its name on August 25, 1995.
Filing Details
The 8-K filing was submitted under the SEC Act of 1934 and is identified by the SEC file number 033-80623. The filing was made on November 10, 2026, and is part of the company's ongoing compliance with regulatory requirements.
Financial Reporting
While the filing indicates that financial statements and exhibits were included, specific figures regarding revenue and expenses were not disclosed. This lack of detail may leave stakeholders seeking further insights into the company's financial health and operational performance.
Future Outlook
The filing does not provide any forward-looking statements or guidance regarding future performance or strategic initiatives, which may leave investors and analysts looking for more clarity on the company's direction.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










